4D Molecular Therapeutics, Inc. Payments of Stock Issuance Costs
4D Molecular Therapeutics, Inc. (FDMT) reported Payments of Stock Issuance Costs of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-05-09
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2023-03-31 was $69.00K, a 71.95% decline year-over-year.
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-12-31 was $468.00K.
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for the quarter ending 2022-09-30 was -$360.00K.
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for fiscal 2022 was $468.00K.
- 4D Molecular Therapeutics, Inc. payments of stock issuance costs for fiscal 2021 was $0.00.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2023-03-31 | $69.00K 10-Q · filed 2024-05-09 | $537.00K derived: sum of 2 quarters · filed 2024-05-09 | $177.00K derived: sum of 3 quarters · filed 2024-05-09 | $291.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $468.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $108.00K derived: sum of 2 quarters · filed 2024-02-29 | $222.00K derived: sum of 3 quarters · filed 2024-02-29 | $468.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | -$360.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$246.00K derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | -$946.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | $114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $360.00K 10-Q · filed 2022-08-11 | -$586.00K derived: sum of 3 quarters · filed 2023-05-11 | -$586.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | $246.00K 10-Q · filed 2023-05-11 | -$700.00K derived: sum of 2 quarters · filed 2023-05-11 | -$700.00K derived: sum of 3 quarters · filed 2023-05-11 | -$700.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$946.00K derived: sum of 2 quarters · filed 2023-03-15 | -$946.00K derived: sum of 3 quarters · filed 2023-03-15 | $0.00 10-K · filed 2023-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $946.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $946.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $946.00K 10-Q · filed 2022-05-12 | |||
| 2020-09-30 | -$348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$374.00K derived: sum of 2 quarters · filed 2021-11-10 | $20.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $368.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $394.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |